Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid PriceSOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) announced today that on July 20, 2010 it received a letter from the Nasdaq Stock Market stating that the minimum bid price of the Company\'s common stock has been below $1.00 per share for 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid ......
Add Comment